Esophagus

Global Capsule Endoscopy Market Projected to Reach $1,020.5 Million by 2030, Propelled by a Strong 9.6% CAGR - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 26, 2023
Medical Devices, Health, Colon, Endoscopy, Capsule endoscopy, Colorectal cancer, Prevalence, Disease, Esophagus, Crohn's disease, Growth, COVID-19, Hospital, Capsule, Patient, Diagnosis, Inflammatory bowel disease, Pharmaceutical industry, Medical device

The global capsule endoscopy market is on a trajectory of significant growth, with expectations of reaching a substantial USD 1,020.5 million by 2030.

Key Points: 
  • The global capsule endoscopy market is on a trajectory of significant growth, with expectations of reaching a substantial USD 1,020.5 million by 2030.
  • The need for accurate and timely diagnosis of these conditions is driving the demand for capsule endoscopy.
  • In 2022, wireless capsule endoscopy dominated the market, driven by increased utilization rates for screening the esophagus, colon, and small intestine.
  • The global capsule endoscopy market presents significant growth opportunities driven by the need for advanced diagnostic tools and the rising prevalence of gastrointestinal disorders.

NeuraSignal’s NovaGuide™ Intelligent Ultrasound System Significantly Outperforms Standard of Care for Detecting Stroke-Associated Heart Defects

Retrieved on: 
Tuesday, October 10, 2023
Patent, Diagnosis, Esophagus, PFO, Physician, Edward Hines, Acquisition, Intelligence, TCD, Brain, RLS, Risk, Heart, Safety, Travel, LOS, TEE, Recurrence, TTE, Principal, Robotics, Service, Neurology, Pathology, Veterans Health Administration, Patient, Medical imaging, Pharmaceutical industry, Stroke

LOS ANGELES, Oct. 10, 2023 (GLOBE NEWSWIRE) -- NeuraSignal, a medical technology and data company specializing in the assessment and management of brain health, today announced the publication of positive results from the BUBL clinical study (#NCT04604015) supporting the safety and superior performance of its NovaGuide Intelligent Ultrasound system in detecting Right to Left Shunt (RLS) — often due to a patent foramen ovale (PFO) — in patients with acute ischemic stroke. The data, published in Stroke, show that the NovaGuide system detected RLS that TTE missed. Importantly, NovaGuide also detected large RLS, which typically require intervention to prevent subsequent ischemic events, that were frequently missed with TTE.

Key Points: 
  • The data, published in Stroke , show that the NovaGuide system detected RLS that TTE missed.
  • Importantly, NovaGuide also detected large RLS, which typically require intervention to prevent subsequent ischemic events, that were frequently missed with TTE.
  • “An accurate assessment for RLS is a critical part of evaluating patients with cryptogenic ischemic stroke.
  • The standard of care for PFO screening is TTE, an ultrasound-based approach in which the ultrasound transducer is moved across the chest to create an image of the heart.

Physicians Urge Alameda City Council to Reject Proposed Lease for Company Run by Former Elon Musk Partner Who Oversaw Deadly Monkey Experiments

Retrieved on: 
Tuesday, October 17, 2023
Medical Devices, Health, Health Technology, Other Science, Research, Science, Dysentery, Esophagus, Physicians Committee for Responsible Medicine, Paralysis, Death, Letter, Vomiting, Brain, Ethics, Animal, Self-harm, University, University of California, Davis, Alameda Point, Alameda, California, Rabbit, Primate, CQD, Seizure, Internal bleeding, Reuters, Mouse, Hodak, Molina Healthcare, Neuralink, Blood, Pharmaceutical industry

A national medical ethics group is urging the Alameda City Council to reject a proposed lease for a medical device company whose CEO recently oversaw debilitating, deadly experiments on monkeys.

Key Points: 
  • A national medical ethics group is urging the Alameda City Council to reject a proposed lease for a medical device company whose CEO recently oversaw debilitating, deadly experiments on monkeys.
  • The company, Science Corp., has applied to occupy Building 11 at Alameda Point, public property owned by the city, where it plans to conduct experiments on primates, rabbits, and mice.
  • Its CEO, Max Hodak, was the co-founder and, until May 2021, president of the brain-computer interface company Neuralink.
  • Hodak started Neuralink with Elon Musk, and the company’s experiments on monkeys at the University of California, Davis, from 2017 to 2020 caused public outcry when they were revealed last year by the nonprofit Physicians Committee for Responsible Medicine.

MCRA Assists Attune Medical on FDA De Novo Marketing Authorization for ensoETM™ Esophageal Thermal Regulating Device

Retrieved on: 
Wednesday, October 11, 2023
Partnership, Senior, Esophagus, Physician, Quality assurance, MS, De novo, US, FHRS, Circulatory system, Culture, Strategic planning, FACC, Clinical trial, Classification, US Foods, Temperature, Patient, FDA, Product code, CMO, MCRA, Heart failure, Attune, PLLC, Operating, US FDA, Medical device, MD, Computer security, Electrophysiology, United States Navy

This new marketing authorization establishes a new Product Code, expanding the classification of ensoETM as a temperature regulation device for esophageal protection during cardiac ablation procedures.

Key Points: 
  • This new marketing authorization establishes a new Product Code, expanding the classification of ensoETM as a temperature regulation device for esophageal protection during cardiac ablation procedures.
  • Attune Medical is the pioneer of using the esophageal space to manage temperature and received its first De Novo authorization in 2015.
  • MCRA's Cardiovascular Regulatory experts assisted Attune Medical through regulatory strategy, pre-submission and De Novo submission to the US FDA utilizing the totality of clinical data available.
  • Together, Attune Medical and MCRA were able to present FDA with a sound regulatory approach, clear framing of complex datasets and a compelling benefit-risk assessment.

Implantica's RefluxStop™ made a substantial impact at the American Foregut Society (AFS)

Retrieved on: 
Tuesday, October 10, 2023
Annual general meeting, General surgery, Esophagus, AFS, Division, European, Deutsche Medizinische Wochenschrift, University, University of Southern California, CEST, Dysphagia, Gastroenterology, CE, University of Milan, Associate, Surgeon, Certification, Clinic, Patient, Gastroesophageal reflux disease, Hiatal hernia, Dentistry, Hospital, GERD

), a medtech company at the forefront of bringing advanced technology into the body, successfully attended the American Foregut Society (AFS) 2023 Annual Meeting held in Dallas, Texas.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, successfully attended the American Foregut Society (AFS) 2023 Annual Meeting held in Dallas, Texas.
  • The meeting included a panel discussion on RefluxStop with 4 leading European KOLs and was moderated by the former president of AFS.
  • The panel reviewed and discussed the promising outcomes data from over 500 RefluxStop procedures performed in Europe.
  • "It is rewarding that outcomes achieved during the CE study can be replicated in a real-world setting.

Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus

Retrieved on: 
Monday, October 2, 2023
Oncology, Health, Surgery, Managed Care, Research, Science, Biotechnology, LGD, AFS, Esophagus, Cancer, Radiofrequency ablation, EAC, Incidence, BE, HGD, Dysplasia, HIV disease progression rates, Patient, Physician, Risk, Report, Annual general meeting, Esophageal cancer, Poster, EET, RFA, Pharmaceutical industry, Medical imaging

The data was presented in a poster at the recent American Foregut Society (AFS) Annual Meeting.

Key Points: 
  • The data was presented in a poster at the recent American Foregut Society (AFS) Annual Meeting.
  • The poster, titled “A Tissue Systems Pathology Test Enables Risk-Aligned Management of Patients with Non-Dysplastic Barrett’s Esophagus: Case Reports from a Gastrointestinal Surgery Center,” can be viewed here .
  • The case study reinforced the ability of TissueCypher to identify NDBE patients at high/intermediate risk for progression to HGD/EAC.
  • Identification of NDBE patients with similar progression risk to LGD enables physicians and their patients to consider risk-aligned upstaging of care to prevent development of EAC and improve their overall health outcomes.

Study Finds Significant Reduction in Esophageal Injury Rate When Using ensoETM™ During Cardiac Radiofrequency Ablation Procedures

Retrieved on: 
Monday, September 25, 2023
Science, Other Science, Biotechnology, Research, General Health, Health, Clinical Trials, Other Health, Radiation, FHRS, De novo, Atrial fibrillation, Esophageal disease, Esophagus, Multimedia, Temperature, Massage chair, AEF, NorthShore University HealthSystem, Cardiac electrophysiology, Hospital, AEF Monotrace, Journal, Patient, Fluoroscopy, Sutter Health, American College, Death, Liquor, Medical device, Doctor of Philosophy, MD

Esophageal injury can occur during ablation procedures for the treatment of atrial fibrillation, and an AEF is the most severe form of injury, resulting in death in most cases.

Key Points: 
  • Esophageal injury can occur during ablation procedures for the treatment of atrial fibrillation, and an AEF is the most severe form of injury, resulting in death in most cases.
  • View the full release here: https://www.businesswire.com/news/home/20230925491005/en/
    A peer-reviewed study in the Journal of the American College of Cardiology: Clinical Electrophysiology (JACC-EP) has found a significant reduction in the rate of atrioesophageal fistulas (AEFs) during cardiac ablation of the left atrium when using Attune Medical’s ensoETM proactive esophageal cooling device compared to luminal esophageal temperature monitoring.
  • The authors concluded that adoption of active esophageal cooling during RF ablation of the left atrium for the treatment of atrial fibrillation was associated with a significant reduction in AEF rate.
  • “This is the first study of the effectiveness of any technique to show a significant benefit in the reduction of AEFs.

CorriXR Therapeutics Announces Deborah Moorad as Its New Chief Executive Officer

Retrieved on: 
Tuesday, September 19, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Genetics, Glioma, CRISPR, Gene editing, Clinical trial, Esophagus, Head, MBA, Multimedia, Neck, Glioblastoma, Lung, ChristianaCare, Drug resistance, CDMO, Patient, Therapy, Disease, Pharmaceutical industry

CorriXR Therapeutics, Inc. , an oncology-focused biotherapeutics company developing breakthrough technology that overcomes drug resistance in solid tumors, announced that Deborah Moorad, MBA, has been named the company’s new chief executive officer.

Key Points: 
  • CorriXR Therapeutics, Inc. , an oncology-focused biotherapeutics company developing breakthrough technology that overcomes drug resistance in solid tumors, announced that Deborah Moorad, MBA, has been named the company’s new chief executive officer.
  • Moorad, who previously served as CEO of Nature Technology Corp., and is an Entrepreneur-in-Residence at Cortado Ventures, succeeds co-founder Eric B. Kmiec, Ph.D., who has been appointed chief scientific officer.
  • Moorad also led a repurposed drug (OKN-007) from animal studies to clinical trial for glioblastoma multiforme.
  • “I’m excited to bring my perspective to an exceptional team of scientists and business leaders,” says Moorad.

New Eosinophilic Gastrointestinal Disorders (EGIDs) Real World Registry Surpasses 1,000 Patient Milestone

Retrieved on: 
Thursday, September 21, 2023
Medical school, University, Eosinophilic esophagitis, PRO, University of North Carolina, Human, Chapel Hill, Esophagus, EGE, Research, Languages of Thailand, Eosinophilic gastroenteritis, Committee, Hepatology, Patient, Data, Division, School, RWE, Diagnosis, MPH, Roger Hawkins (drummer), Chair, Disease, Geography, Pharmaceutical industry, Nursing, MD, Gastroenterology, Medicine

DURHAM, N.C., Sept. 21, 2023 /PRNewswire/ -- Launched as a response to market interest and high unmet need, today real-world evidence (RWE) leader Target RWE announced a milestone achievement of surpassing 1,000 patients enrolled in the company's eosinophilic gastrointestinal disorders (EGIDs) disease state registry.

Key Points: 
  • Target RWE expands its gastroenterology footprint with 1,000+ patients enrolled in its EGIDs disease state registry.
  • They affect different parts of the digestive system, from the esophagus to the large intestine and may be linked to food allergen exposure.
  • EGIDs include eosinophilic esophagitis (EoE) and eosinophilic gastroenteritis (EGE) based on the location of the disease.
  • The data is currently being curated for analyses to further characterize disease natural history, the EGID patient journey, and the impact of co-morbidities.

Implantica announces two independent scientific presentations on RefluxStop™ from the 2023 Annual ISDE conference

Retrieved on: 
Tuesday, September 19, 2023
Certification, Surgeon, Disease, University, Safety, ISDE, NCI-designated Cancer Center, Research, University of Veterinary Medicine Vienna, Patient, General Hospital, CEST, EFS, General surgery, International Society, Medical device, Dentistry, Esophagus

), a medtech company at the forefront of bringing advanced technology into the body, was honored to see multiple independent scientific podium presentations on RefluxStop™, an innovative procedure for the treatment of acid reflux, showcased at the 2023 International Society for Diseases of the Esophagus (ISDE) meeting in Toronto, Canada.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, was honored to see multiple independent scientific podium presentations on RefluxStop™, an innovative procedure for the treatment of acid reflux, showcased at the 2023 International Society for Diseases of the Esophagus (ISDE) meeting in Toronto, Canada.
  • The presentations covering RefluxStop™ safety and efficacy real-world data on 85 patients and an overview of the RefluxStop™ procedure were featured as part of this year's ISDE scientific program, on September 8th, 2023.
  • Once again, we congratulate Prof. Schoppmann and Dr. Lehmann for their distinguished leadership in the field of acid reflux," said Dr. Peter Forsell, CEO of Implantica.
  • The company's Certified Adviser is FNCA Sweden AB, [email protected]
    The information was sent for publication, through the agency of the contact person set out above, on September 19, 2023, at 08:00 a.m. (CEST).